MannKind Corporation - Common Stock (NQ:MNKD)

3.650 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

March 11, 2024

From MannKind

Via GlobeNewswire

Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out' ↗

March 08, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he needs to do more work on Sprout Social, Inc. (NASDAQ: SPT) as it is in a "hot spot, but the stock is not making money. And because the...

Via Benzinga

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

March 05, 2024

Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)

From MannKind

Via GlobeNewswire

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

MannKind Earnings Preview ↗

February 26, 2024

Via Benzinga

A Preview Of MannKind's Earnings ↗

November 06, 2023

Via Benzinga

MannKind Corporation Announces Participation at Upcoming Conferences

March 04, 2024

From MannKind

Via GlobeNewswire

MannKind (MNKD) Q4 2023 Earnings Call Transcript ↗

February 28, 2024

MNKD earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

February 27, 2024

Conference Call to Begin Today at 5:00 p.m. (ET)

From MannKind

Via GlobeNewswire

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

February 20, 2024

From MannKind

Via GlobeNewswire

Why MannKind Stock Soared 19% Higher on Tuesday ↗

August 08, 2023

The biotech delivered quite an impressive earnings report.

Via The Motley Fool

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

February 15, 2024

From MannKind

Via GlobeNewswire

3 Biotech Stocks to Sell in January Before They Crash and Burn ↗

January 25, 2024

The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.

Via InvestorPlace

MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

January 02, 2024

From MannKind

Via GlobeNewswire

MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 28, 2023

From MannKind

Via GlobeNewswire

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 02, 2024

Shares of Longboard Pharmaceuticals, Inc.

Via Benzinga

Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 20, 2023

Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.

Via Benzinga

High-Yield Haven: 3 Dividend Stocks to Secure Now ↗

December 05, 2023

These are three different dividend stocks that have a great dividend yield and offer a reliable source of income.

Via InvestorPlace

MannKind (MNKD) Q3 2023 Earnings Call Transcript ↗

November 07, 2023

MNKD earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

MannKind Corporation Reports 2023 Third Quarter Financial Results

November 07, 2023

From MannKind

Via GlobeNewswire

MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes

November 06, 2023

From MannKind

Via GlobeNewswire

MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023

October 31, 2023

From MannKind

Via GlobeNewswire

MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent

October 30, 2023

From MannKind

Via GlobeNewswire

MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback' ↗

October 10, 2023

Shares of MannKind Corp (NASDAQ: MNKD) were climbing in early trading on Tuesday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗

October 10, 2023

Via Benzinga

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth ↗

September 07, 2023

Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.

Via InvestorPlace

MannKind Corporation Announces Participation at Upcoming Conferences

September 05, 2023

From MannKind

Via GlobeNewswire

3 Biotech Stocks to Sell in August Before They Crash and Burn ↗

August 14, 2023

These biotech stocks are set to crash and burn, so it's probably a good idea for investors to sell in August, before it's too late.

Via InvestorPlace

Intuit To Rally More Than 20%? Here Are 10 Other Analyst Forecasts For Monday ↗

August 14, 2023

Keybanc lowered the price target for Bumble Inc. (NASDAQ: BMBL) from $25 to $24. Keybanc analyst Justin Patterson maintained an Overweight rating. Bumble shares rose 0.9% to $16.65 in pre-market...

Via Benzinga

Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 08, 2023

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.